U S Global Investors Inc Supernus Pharmaceuticals, Inc. Transaction History

U S Global Investors Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$20.2 - $25.05 $596,182 - $739,325	-29,514 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $63,233 - $92,093	3,700 Added 14.33%	29,514 $701,000
Q1 2020 May 04, 2020	SELL	$14.45 - $24.69 $139,962 - $239,147	-9,686 Reduced 27.28%	25,814 $464,000
Q4 2019 Feb 12, 2020	BUY	$19.93 - $29.13 $707,515 - $1.03 Million	35,500 New	35,500 $842,000
Q1 2018 May 15, 2018	SELL	$37.15 - $46.9 $1.17 Million - $1.47 Million	-31,400 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$36.4 - $42.6 $21,840 - $25,560	-600 Reduced 1.88%	31,400 $1.25 Million
Q3 2017 Nov 13, 2017	SELL	$36.75 - $49.65 $456,030 - $616,106	-12,409 Reduced 27.94%	32,000 $1.28 Million
Q2 2017 Aug 17, 2017	BUY	N/A	44,409	44,409 $1.91 Million

303

60.6M

22.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.75B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of U S Global Investors Inc, based on Form 13F filings with the SEC.

Stay updated on U S Global Investors Inc with notifications on news.